ClinicalTrials.gg
RecruitingNCT07302672Updated Jul 14, 2026

Humanistic Continuing Care Via WeChat for Patients Undergoing Thermal Ablation of Papillary Thyroid Carcinoma

An interventional study of Humanistic Continuing Care via WeChat and Usual Care (No Structured WeChat Program) in Papillary Thyroid Carcinoma, sponsored by Ming-an Yu. Recruiting at 1 site in China. Open to participants aged 16 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Ming-an Yu · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
16 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Thyroid Cancer, Papillary with a site in China — 24 open to participants now, 25 under way, 1 of them phase 3. Thyroid Cancer, Papillary · China.

Planned enrollment
14th of 21
108 · median 170
Started
2025
with 4 others
No phase
14 of 40
7 open now
Primary completion
2026-06
later than 12 of 24 live
Registered
36th of 40
by date
Lead sponsor
2 of 40
Ming-an Yu

Among the 40 studies in Thyroid Cancer, Papillary with a site in China, this one is the 14th largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2025, is one of 14 with no phase, reaches primary completion later than 12 of the 24 other live ones, and was the 36th registered.

Thyroid Cancer, Papillary

186 studies on the registry are indexed under Thyroid Cancer, Papillary; 50 are open to participants now.

Browse Thyroid Cancer, Papillary studies →

Open to participants now

24 of the 40 studies in Thyroid Cancer, Papillary with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 31 Thyroid Cancer, Papillary studies recruiting now, 18 (58%) set no upper age limit and 8 (26%) stop at 75 or younger; 13 take children under 18; 3 take healthy volunteers.

This study: 16 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Thyroid Cancer, Papillary with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test whether human-centered nursing care lowers emotional distress and improves quality of life for people who are awake during thyroid thermal ablation. The procedure uses local anesthesia, so participants remain awake and may feel tense. Human-centered care focuses on emotional support, clear communication, comfort, and follow-up, and it may improve the experience and recovery for patients.

The main questions are:

Does human-centered nursing care reduce emotional distress levels in patients undergoing thyroid thermal ablation?

Does human-centered nursing care improve patient quality of life after thyroid thermal ablation?

If there is a comparison group: Researchers will compare human-centered nursing care to usual nursing care to see if human-centered care leads to lower emotional distress and higher quality of life.

Participants will:

Receive either human-centered nursing care or usual nursing care.

Complete questionnaires before, during, and after the procedure to measure emotional distress, quality of life, pain, and satisfaction with care.

Have their vital signs and quality of life tracked during and after the procedure.

Have their adherence to care plans and any complications monitored.

The main outcomes are emotional distress levels and quality of life. Other outcomes include pain and vital signs during the procedure, satisfaction with care, and complication rates. Results may guide better care for people undergoing small, minimally invasive treatments while awake.

03

Conditions studied

  • Papillary Thyroid Carcinoma

Keywords

  • papillary thyroid carcinoma
  • thermal ablation
  • humanistic care
  • continuity care
  • Wechat
  • anxiety
  • quality of life
04

Who can participate

Ages eligible
16 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 16-60 years; scheduled for thyroid thermal ablation
  • Papillary thyroid carcinoma (PTC)
  • Number of target lesions \<= 3
  • Largest lesion diameter \<= 2 cm; clinical stage T1N0M0 by imaging
  • Awake and able to cooperate under local anesthesia

Owns a smartphone and can use WeChat

Exclusion criteria

Exclusion Criteria:

  • Serious medical comorbidities or cognitive impairment that precludes participation
  • Prior thyroid surgery or thermal ablation
  • Unwilling or unable to join the WeChat group or complete postoperative follow-up
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Humanistic Continuing Care via WeChat

    Behavioral: Humanistic Continuing Care via WeChat

  • Active comparator
    Usual Care (No Structured WeChat Program)

    Procedure: Usual Care (No Structured WeChat Program)

Interventions

  • BehavioralHumanistic Continuing Care via WeChat

    Description: Structured, humanistic peri-operative nursing program delivered through WeChat in addition to routine care. Components: pre-procedure needs assessment and expectation setting; brief coping skills coaching (e.g., paced breathing); intra-procedure step-by-step explanations, reassurance, and comfort measures; post-procedure education, recovery guidance, and psychosocial support; symptom monitoring with red-flag escalation; medication/wound-care and appointment reminders; on-demand messaging during service hours; optional caregiver engagement. Delivery \& Schedule: Nurse-led. One pre-procedure session; intra-procedure support on the day of ablation; post-procedure WeChat check-ins at least weekly plus on-demand messaging for 12 weeks. Fidelity tracked via standardized checklists. Arm(s): Experimental - Humanistic Continuing Care via WeChat.

  • ProcedureUsual Care (No Structured WeChat Program)

    Participants receive standard peri-operative nursing and institutional discharge materials, including routine pre-procedure counseling, standard intra-procedure monitoring, printed/posted instructions for home care, and follow-up per usual practice (e.g., clinic visit or routine phone call). They may contact the clinic using standard channels as needed, but there is no scheduled, structured WeChat outreach or humanistic continuing-care protocol.

06

What researchers measure

Primary outcomes

  1. Change in emotion distress from baseline to post-procedure (HADS)

    Time frame: From enrollment to the end of treatment at 3 months

  2. Change in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 scores from baseline to 3 months

    Time frame: From enrollment to the end of treatment at 3 months

  3. Change in Thyroid Cancer-Specific Quality of Life Questionnaire scores from baseline to 3 months

    Time frame: From enrollment to 3 months after end of treatment

Secondary outcomes

  1. Intraoperative pain intensity (Visual Analog Scale)

    Pain intensity during the procedure will be assessed using a Visual Analog Scale (VAS; 0-100 mm, where 0 indicates no pain and 10 indicates the worst imaginable pain). A single VAS score will be recorded during the intraoperative period.

    Time frame: Intraoperative period (during the procedure)

  2. Patient satisfaction with nursing care (Newcastle Satisfaction with Nursing Scale, NSNS)

    Time frame: Postoperative Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Undecided at this time; a final decision about IPD sharing will be made after publication in consultation with the institution's data governance and ethics committees.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Jun 2026, 6 months.

Of 26 interventional studies with no phase under Thyroid Cancer, Papillary, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 71. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2025
First posted
Dec 24, 2025
StartActual
Dec 15, 2025
Primary completionActual
Jun 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07302672
Lead sponsor
Ming-an Yu
Responsible party
Ming-an Yu (Head of department of intervention medicine, China-Japan Friendship Hospital) — Sponsor-investigator
First posted
Dec 24, 2025
Start date
Dec 15, 2025
Primary completion
Jun 30, 2026
Completion
Dec 31, 2026 (estimated)
Last update
Jul 14, 2026

Study contacts

ming-an yu, MD
Contact
yma301@163.com
84205756

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion